CN107510839A - A kind of immunomodulator and its preparation method and application - Google Patents
A kind of immunomodulator and its preparation method and application Download PDFInfo
- Publication number
- CN107510839A CN107510839A CN201710774978.7A CN201710774978A CN107510839A CN 107510839 A CN107510839 A CN 107510839A CN 201710774978 A CN201710774978 A CN 201710774978A CN 107510839 A CN107510839 A CN 107510839A
- Authority
- CN
- China
- Prior art keywords
- immunomodulator
- preparation
- cell
- cells
- stimulating factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2073—IL-11
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
Abstract
The application belongs to biomedicine technical field, and in particular to a kind of immunomodulator and its preparation method and application.This application provides a kind of immunomodulator, comprising：NKT cells, dendritic cells, IL 11, macrophage colony stimulating factor of recombinant human granulocyte, human serum albumin and medically acceptable solvent, and the preparation method of the immunomodulator and the application in prevention and treatment systemic loupus erythematosus medicine is prepared.The immunomodulator is from immunoregulatory angle, using the immunity regulatory cell of both differentiation and maturations of BMDC and NKT cells, immunoregulation effect can be played immediately after feedback, joint IL 11 and macrophage colony stimulating factor of recombinant human granulocyte, the component ratio of the immunocyte of sustainable improvement body, fundamentally solves the problems, such as body immune system disorder.
Description
Technical field
The invention belongs to biomedicine technical field, and in particular to a kind of immunomodulator and its preparation method and application.
Background technology
Systemic loupus erythematosus (Systemic Lupus Erythematosus, SLE) be a kind of diffusivity, it is systemic from
Body immunological disease.Under the interaction of the various factors such as environmental factor, estrogen level, T lymphocytes are caused to reduce, T suppresses thin
Born of the same parents' function reduces, B cell hyperplasia, produces substantial amounts of autoantibody, and combine to form phase with internal corresponding autoantigen
The immune complex answered, it is deposited on the positions such as skin, joint, thin vessels, glomerulus.In the presence of complement, cause acute and chronic
Inflammation and necrosis (such as lupus nephritis), or antibody cause cytoclasis (such as red thin directly with histocyte antigenic action
The specific antigen of born of the same parents, lymphocyte and blood platelet wall combine with corresponding autoantibody, cause hemolytic anemia, lymph respectively
Cytopenia and thrombopenia).SLE can involve the multiple systems of body, including joint, muscle, kidney, nervous system,
Hematological system, heart and digestive system etc., pathological lesion is brought to the multiple tissue internal organs of patient.
Early diagnosis and early treatment are emphasized in SLE treatment, to avoid or delay the pathological lesion of tissue.Existing curative
Thing mainly includes NSAIDs, antimalarial, glucocorticoid and immunodepressant, wherein NSAIDs, antimalarial
It is mainly used in that symptom is slight with glucocorticoid, the patient symptom without obvious visceral lesion improves treatment, exempts to prevent or reduce
Damage of the epidemic disease cell to internal organ；Immunodepressant such as endoxan, imuran etc. are one of the active drugs for treating SLE, energy
Effective induced disorders are alleviated, and prevent and reverse pathological development, improve prognosis at a specified future date, its defect essentially consists in long-term use, meeting
It is suppressed body's immunity, it is impossible to fundamentally to treat body immune system disorder and Relapse rate.
Systemic loupus erythematosus gives anti-inflammatory treatment or immunosuppressive therapy as a kind of autoimmune disease, its
Main function is to improve or the short-term development of the tissue disease state of an illness, and long-term use is easily caused immune system dysfunction, no
Benefit can be brought to disease long-run development.Therefore, some scholars propose that the treatment of systemic loupus erythematosus should carry out immunological regulation,
By influence its regulatory T cells differentiation, cytokine secretion, immunoglobulin all too many levels such as generation block and improve
Disease process, rather than immunosupress.At present, the temporarily application without immunomodulator in Therapy for Systemic Lupus Erythematosus.
The content of the invention
In order to solve the above-mentioned technical problem, the invention provides a kind of immunomodulator for treating SLE and preparation method thereof,
Treatment of the said preparation for SLE has preferable effect.
The concrete technical scheme of the present invention is as follows：
A kind of immunomodulator, including：NKT cells, dendritic cells, IL-11, recombinant human granulocyte-macrophage colony
Stimulating factor, human serum albumin and medically acceptable solvent.
Dendritic cells played an important role in the balance for maintaining immune system, and there is antigen to offer and be immunized for it
Activation, immunoregulation effect, the effect such as maintenance and induction, the capture to apoptotic cell of immune tolerance.SLE patient's bodies
T cell functional defect be present, further investigations have shown that the functional defect of T cell is lacked by potential antigen presenting cell function
Caused by falling into, and dendritic cells is most important antigen presenting cell, so the functional defect of dendritic cells is to cause T cell
The main reason for functional defect.It is different in the extremely caused humoral immune reaction of SLE patient's bodies either B cell or T cell
Cell immune response caused by often all changes with the function of dendritic cells direct relation.
NKT cells mainly include immunological regulation and CDCC, after NKT cells are upset, can secrete substantial amounts of
IL-11, gamma interferon, granulocyte-macrophage colony stimutaing factor, interleukin-11 3 and other cell factors and chemotactic factor (CF),
Play immunoregulation effect.
Systemic loupus erythematosus causes the granulocyte number in hematological system to reduce, and recombinant human granulocyte-macrophage colony
Stimulating factor can act on HPC, promote it to breed and break up, and stimulates grain, mononuclear macrophage ripe, promotes into
Ripe cell discharges to peripheral blood, and can promote macrophage and bite the multiple functions of acidic cell.
IL-11 be hematopoieticmicroenviron-ment stroma cell caused by multifunctional cytokine, have the obvious work for promoting blood platelet regenerating
With, in the Proliferation, Differentiation of marrow hemopoietic stem cells, can stimulating megakaryocyte it is ripe and be divided into blood platelet.IL-11 is applied to
Patients with systemic lupus erythematosus platelet reduces patient and all achieves the effect of certain, it was demonstrated that IL-11 can make the macronucleus of patient thin
Born of the same parents' maturation is divided into blood platelet.
Preferably, the concentration of the NKT cells is 5 × 107~1 × 108cell/mL；The concentration of the dendritic cells is
5×107~1 × 108cell/mL；The concentration of the IL-11 is 10~30ng/mL；The recombinant human granulocyte-macrophage collection
The concentration of G-CSF is 20~40ng/mL；The concentration of the human serum albumin is 1%~5%.
It is highly preferred that the concentration of the IL-11 is 20ng/mL；The recombinant human granulocyte-macrophage colony stimulate because
The concentration of son is 30ng/mL；The concentration of the human serum albumin is 2%.
Preferably, the solvent is selected from physiological saline or 5% glucose injection solution.
Preferably, the preservation condition of the immunomodulator is 0~4 DEG C.
It is present invention also offers the preparation method of above-mentioned immunomodulator, human serum albumin, IL-11, recombined human grain is thin
Born of the same parents' macrophage colony stimulatory factor, NKT cells and dendritic cells mix in a solvent, obtain the immunomodulator.
Preferably, the NKT cells and dendritic cells are differentiated by PMNC induction.
It is highly preferred that the derivant of the NKT cells is IL-2, IL-15 and IL-21；
It is furthermore preferred that the dendritic cells derivant be human granulocyte-macrophage colony stimulating factor, IL-4 and
TNF-α。
Present invention also offers the immunomodulator that above-mentioned immunomodulator or above-mentioned preparation method obtain to prepare in advance
Application in anti-or medicament for treating systemic lupus erythematosus.
Beneficial effects of the present invention mainly include it is following some：
(1), can be immediately after feedback using the immunity regulatory cell of both differentiation and maturations of BMDC and NKT cells
Effect is played, joint IL-11 is used, and both caused immune effects after feedback of enhancing, improves the hyperfunction situation of immunity of organism,
Alleviate the state of an illness；
(2) type cytokine of macrophage colony stimulating factor of recombinant human granulocyte two, sustainable regulation and control machine are used
The candidate stem cell in internal portion enters division cycle, persistently improves the component ratio of the immunocyte of body, fundamentally solves
The problem of body immune system disorder；
(3) PMNC is selected, carries out the differentiation culture of NKT cells and BMDC, while is added thin
Intracellular cytokine, preparation can play a role at once after meeting is defeated；IL-11 and macrophage colony stimulating factor of recombinant human granulocyte meeting
Candidate stem cell is stimulated persistently to break up, it is continual and steady the effect of guarantee.
Embodiment
In order to solve the above-mentioned technical problem, the invention provides a kind of immunomodulator for treating SLE and preparation method thereof,
Treatment of the said preparation for SLE has preferable effect.
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only part of the embodiment of the present invention, rather than whole embodiments.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all
Belong to the scope of protection of the invention.
Embodiment 1
1. the separation and Extraction of PMNC
(1) anticoagulant tube equipped with peripheral blood is put into aseptic operating platform, will be outer in anticoagulant tube with disposable pipette
All blood is transferred in 50mL centrifuge tubes, according to 1:1 volume ratio adds physiological saline, mixes；
(2) blood dilution liquid that step (1) obtains is slowly added into the SepMate equipped with lymphocyte separation medium to centrifuge
(blood dilution liquid in pipe：Lymph separating liquid=2:1), 700g takes supernatant after centrifuging 15min；
(3) supernatant is resuspended with the culture mediums of RPMI 1640,500g centrifugations 5min removes supernatant, obtains the single core of peripheral blood
Cell precipitation；
(4) PMNC is precipitated and adds RPMI 1640+5%FBS complete mediums and be resuspended, by 1 ×
106Cells/mL concentration is inoculated in blake bottle, is placed in 37 DEG C, 5%CO22h is cultivated in incubator, is gently blown and beaten, is discarded outstanding
Floating non-adherent cell, that is, obtain adherent PMNC.
The culture of 2.NKT cells
(1) take adherent PMNC, add cell factor IL-2 (500U/mL), IL-15 (50ng/mL) and
IL-21 (50ng/mL), continues to cultivate；
(2) cell is observed daily, carries out fluid infusion according to cell proliferative conditions at the 5th day, cell has propagation then to add containing IL-
2 (500U/mL) and IL-15 (50ng/mL) complete medium, and cell density is adjusted as 1 × 106cells/mL；
(3) added every 3 days according to cell proliferative conditions containing the complete of IL-2 (500U/mL) and IL-15 (50ng/mL)
Culture medium, continue culture 9 days, obtain NKT cells.
3. the culture of dendritic cells
(1) take adherent PMNC, according to μ g/mL of human granulocyte-macrophage colony stimulating factor 1,
IL-4 10ng/m final concentration adds human granulocyte-macrophage colony stimulating factor and IL-4, continues to cultivate, changes within every 3.5 days
Liquid is once；
(2) culture added TNF-α 30ng/mL to the 7th day, and harvest suspension cell obtains dendritic cells within the 8th day.
The streaming of 4.NKT cells and dendritic cells is identified
Above-mentioned NKT cells and dendritic cells are taken respectively, are made 1 × 106Cells/mL cell suspension, added toward NKT
Each 5 μ L of CD3, CD56 antibody, BMDC add each 5 μ L of HLA-DR, CD80, CD86, and lucifuge is incubated 20min at room temperature, together
When set blank control, 1500r/min centrifugations, abandon supernatant, upper machine testing after being resuspended with the basal mediums of RMPI 1640.
NKT cell streaming testing results are as shown in table 1, and streaming qualification result shows that NKT cells have higher purity.
Table 1.NKT cell streaming qualification results
| CD3 | CD3+CD56+ | |
| Examine for the first time | 90.6% | 36.7% |
| Second of detection | 92.8% | 40.1% |
| Third time detects | 91.5% | 38.2% |
The flow cytometer detection result of dendritic cells is as shown in table 2, and it is higher that streaming qualification result shows that BMDC has
Purity.
The dendritic cells streaming qualification result of table 2.
| CD80 | CD86 | HLA-DR | |
| Examine for the first time | 82.1% | 70.4% | 96.7% |
| Second of detection | 83.6% | 73.1% | 98.7% |
| Third time detects | 79.8% | 70.5% | 96.2% |
5. the preparation of immunomodulator
(1) human serum albumin is added in physiological saline, to final concentration of 2%；
(2) by 20ng/mL IL-11,30ng/mL recombinant granulocyte macrophage colony_stimulating factor (rhGM-CSF)
Add in the physiological saline containing 2% human serum albumin, mix；
(3) by NKT cells and BMDC according to 5 × 107~1 × 108It is white that cell/mL concentration adds blood containing someone
In albumen and the physiological saline of cell factor, preserved under the conditions of being placed in 4 DEG C after fully mixing.
3 kinds of immunomodulators being formulated as shown in table 3 are prepared according to above-mentioned steps.
The different immunomodulator each component ratios of table 3.
Embodiment 2
1.SLE model mouses and normal mouse
SLE model mouses are Epstein-Barr virus membranous antigen BLLF1 gene transgenic mices, 56, female, 30~40g of body weight；Just
Normal 30~40g of mouse weight (8), purchased from Zhongshan University's medical board Animal Experimental Study center.
2. animal packet and administration
Normal mouse is used to be used as blank group, and SLE model mouse stochastic averaginas are divided into 7 groups, respectively model group, control group 1,
Control group 2, control group 3, experimental group 1, experimental group 2 and experimental group 3, and according to administering mode drug treatment shown in table 4.
The experiment packet of table 4 and administration
| Packet | Administration | Administration time |
| Blank group | Physiological saline | 1 time a day, continuous tail vein injection 14 days |
| Model group | Physiological saline | 1 time a day, continuous tail vein injection 14 days |
| Control group 1 | Re-injection 'Xuebijing ' injection | 1 time a day, continuous tail vein injection 14 days |
| Control group 2 | Glucocorticoid | 1 time a day, continuous tail vein injection 14 days |
| Control group 3 | Immunodepressant imuran | 1 time a day, continuous tail vein injection 14 days |
| Experimental group 1 | Immunomodulator A | Every 5 days 1 time, continuous tail vein injection 15 days |
| Experimental group 2 | Immunomodulator B | Every 5 days 1 time, continuous tail vein injection 15 days |
| Experimental group 3 | Immunomodulator C | Every 5 days 1 time, continuous tail vein injection 15 days |
3. Testing index
After administration terminates, mouse plucks eye and takes blood, 1500rpm room temperatures centrifugation 15min, takes serum 2500rpm to centrifuge again
15min, creatinine, urea nitrogen, INF- α, immunoglobulin M (IgM), immunoglobulin G in blood are detected with kit respectively
(IgG), the level of complement component 3 and complement 4.
Systemic loupus erythematosus can cause injury of kidney, further influence nephridial tissue function, and creatinine and urea nitrogen are to weigh kidney
One of important indicator of function, INF- α are one of important indicators for weighing Renal tissues damage.Creatinine in each group mice serum,
Urea nitrogen and INF- α content are as shown in table 5.
Data show that creatinine, urea nitrogen, the INF- α of model group are above blank group, have pole significant difference (P<
0.001), illustrate that three Testing index of model group meet needed for experiment.
For control group 1~3 compared with model group, creatinine, urea nitrogen, INF- α are below model group, but are anticipated without statistics
Justice (P>0.05) illustrate that 1~3 couple of alleviation SLE of the control group state of an illness is not notable.
For experimental group 1~3 compared with model group, creatinine, urea nitrogen, INF- α are below model group, and have statistical significance
(P<0.05)；Compared with blank group, (P is not statistically significant>0.05), illustrate that 1~3 pair of experimental group can effectively alleviate SLE's
The state of an illness.
The content of creatinine, urea nitrogen and INF- α in each group mice serum of table 5.
| Packet | Creatinine (μm ol/L) | Urea nitrogen (mmol/L) | INF-α(pg/mL) |
| Blank group | 23.56±1.95 | 5.68±0.84 | 52.158±28.467 |
| Model group | 36.91±2.04** | 13.97±2.64** | 120.623±42.09* |
| Control group 1 | 29.25±3.18 | 10.04±3.37 | 80.652±51.76 |
| Control group 2 | 30.38±2.56 | 9.15±2.45 | 86.745±18.39 |
| Control group 3 | 28.13±3.75 | 9.08±3.81 | 79.886±20.62 |
| Experimental group 1 | 22.41±1.67# | 5.24±1.75# | 50.054±22.81# |
| Experimental group 2 | 21.91±1.48# | 5.06±1.33# | 51.489±23.47# |
| Experimental group 3 | 23.85±2.46# | 5.51±1.94# | 50.647±21.55# |
* represent that compared with to blank photo group there is significant difference, P<0.05；
* is represented compared with blank control group, has pole significant difference, P<0.01；
# is represented compared with model group, has significant difference, P<0.05；
## is represented compared with model group, has pole significant difference, P<0.01.
Systemic loupus erythematosus is a kind of chronic auto-immune disease of Multisystem damage, can involve skin joint and in
Pivot nervous system etc., excessively produces relevant with a variety of autoantibodies, detects serum antibody and level of complement and can be good at reacting
Immunity of organism activates degree.IgM, IgG, complement component 3 and complement 4 change are as shown in table 6 in each group mice serum, and data are shown,
Blank group with model group, control group 1~3, experimental group 1~3 IgM and complement component 3 compared with, without statistical significance, P>
0.05。
The IgG and complement 4 of model group are above blank group, have significant difference (P<0.05), illustrate that two detection refers to
Reference symbol is closed needed for experiment.
For control group 1~3 compared with model group, IgG and complement 4 are below model group, but do not have statistical significance (P>
0.05) illustrate that 1~3 couple of alleviation SLE of the control group state of an illness is not notable.
For experimental group 1~3 compared with model group, IgG and complement 4 are below model group, and have statistical significance (P<
0.05)；Compared with blank group, (P is not statistically significant>0.05), illustrate that 1~3 pair of experimental group can effectively alleviate SLE disease
Feelings.
IgM, IgG, complement component 3 and complement 4 content in each group mice serum of table 6.
* represent that compared with to blank photo group there is significant difference, P<0.05；
* is represented compared with blank control group, has pole significant difference, P<0.01；
# is represented compared with model group, has significant difference, P<0.05；
## is represented compared with model group, has pole significant difference, P<0.01.
Claims (8)
- A kind of 1. immunomodulator, it is characterised in that including：NKT cells, dendritic cells, IL-11, recombinant humangranulocyte are huge Phagocyte colony stimulating factor, human serum albumin and medically acceptable solvent.
- 2. immunomodulator according to claim 1, it is characterised in that the concentration of the NKT cells is 5 × 107~1 × 108cell/mL；The concentration of the dendritic cells is 5 × 107~1 × 108cell/mL；The concentration of the IL-11 is 10~30ng/mL；The concentration of the macrophage colony stimulating factor of recombinant human granulocyte is 20~40ng/mL；The concentration of the human serum albumin is 1%~5%.
- 3. immunomodulator according to claim 1, it is characterised in that the solvent is selected from physiological saline or 5% grape Sugar injection solution.
- 4. immunomodulator according to claim 1, it is characterised in that the preservation condition of the immunomodulator is 0~4 ℃。
- 5. the preparation method of the immunomodulator described in a kind of Claims 1-4 any one, it is characterised in that by the people Blood albumin, IL-11, macrophage colony stimulating factor of recombinant human granulocyte, NKT cells and dendritic cells mix in a solvent Close, obtain the immunomodulator.
- 6. preparation method according to claim 5, it is characterised in that the NKT cells and dendritic cells are by peripheral blood Mononuclearcell induction differentiates.
- 7. preparation method according to claim 6, it is characterised in that the derivant of the NKT cells is IL-2, IL-15 And IL-21；The dendritic cells derivant is human granulocyte-macrophage colony stimulating factor, IL-4 and TNF-α.
- 8. the preparation side described in immunomodulator or claim 5 to 7 any one described in Claims 1-4 any one Application of the immunomodulator that method obtains in prevention or medicament for treating systemic lupus erythematosus is prepared.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710774978.7A CN107510839A (en) | 2017-08-31 | 2017-08-31 | A kind of immunomodulator and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710774978.7A CN107510839A (en) | 2017-08-31 | 2017-08-31 | A kind of immunomodulator and its preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107510839A true CN107510839A (en) | 2017-12-26 |
Family
ID=60724993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710774978.7A Pending CN107510839A (en) | 2017-08-31 | 2017-08-31 | A kind of immunomodulator and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107510839A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114134111A (en) * | 2021-12-07 | 2022-03-04 | 珠海贝索细胞科学技术有限公司 | Immune cell activator and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8241621B2 (en) * | 2006-12-18 | 2012-08-14 | Medistem Laboratories | Stem cell mediated treg activation/expansion for therapeutic immune modulation |
| CN103520150A (en) * | 2012-07-06 | 2014-01-22 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Medical application of vitamin E and vitamin E derivatives serving as G-CSF (granulocyte colony-stimulating factor) secretion inductive agent and cell mobilization agent |
| CN106456744A (en) * | 2014-04-01 | 2017-02-22 | 鲁比厄斯治疗法股份有限公司 | Methods and compositions for immunomodulation |
-
2017
- 2017-08-31 CN CN201710774978.7A patent/CN107510839A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8241621B2 (en) * | 2006-12-18 | 2012-08-14 | Medistem Laboratories | Stem cell mediated treg activation/expansion for therapeutic immune modulation |
| CN103520150A (en) * | 2012-07-06 | 2014-01-22 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Medical application of vitamin E and vitamin E derivatives serving as G-CSF (granulocyte colony-stimulating factor) secretion inductive agent and cell mobilization agent |
| CN106456744A (en) * | 2014-04-01 | 2017-02-22 | 鲁比厄斯治疗法股份有限公司 | Methods and compositions for immunomodulation |
Non-Patent Citations (4)
| Title |
|---|
| 张华勇 等: "系统性红斑狼疮患者骨髓间充质干细胞细胞因子分泌及其病情活动的相关性研究", 《现代临床医学生物工程学杂志》 * |
| 李莉 等: "抗人血白蛋白单克隆抗体的制备及其免疫金标试纸条的研制", 《中国卫生检验杂志》 * |
| 邹原方 等: "系统性红斑狼疮患者外周血CD3+CD56+自然杀伤细T细胞的表达及临床意义", 《国际检验医学杂志》 * |
| 郭文静 等: "系统性红斑狼疮患者外周血浆细胞样树突状细胞的变化及意义", 《蚌埠医学院学报》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114134111A (en) * | 2021-12-07 | 2022-03-04 | 珠海贝索细胞科学技术有限公司 | Immune cell activator and preparation method and application thereof |
| CN114134111B (en) * | 2021-12-07 | 2023-08-18 | 珠海贝索细胞科学技术有限公司 | Immune cell activator and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Immunomodulatory effect of Ganoderma atrum polysaccharide on CT26 tumor-bearing mice | |
| CN105524880A (en) | Construction method of immune cell bank | |
| CN107510839A (en) | A kind of immunomodulator and its preparation method and application | |
| CN105018427B (en) | A kind of DC cell culture processes of enhanced CT L immune responses | |
| US20210238549A1 (en) | Use of memory lymphocyte population in liver cancer treatment | |
| Luan et al. | Umbilical cord blood transplantation supplemented with the infusion of mesenchymal stem cell for an adolescent patient with severe aplastic anemia: a case report and review of literature | |
| CN104352521B (en) | Prepare the method for calf spleen extract and the application in antitumor and immunological regulation | |
| Sarfraz | Effect of camel milk supplementation on blood parameters and liver function of hepatitis patients | |
| Bradley et al. | Immunotoxicity of 180 day exposure to polydimethylsiloxane (silicone) fluid, gel and elastomer and polyurethane disks in female B6C3F1 mice | |
| Storey et al. | An overview of the immune system. | |
| Gramajo Lopez et al. | Improvement of myelopoiesis in cyclophosphamide-immunosuppressed mice by oral administration of viable or non-viable lactobacillus strains | |
| CN107519207A (en) | A kind of immunosuppressant cell preparation and its preparation method and application | |
| Wöckel et al. | Inflammatory breast diseases during lactation: health effects on the newborn—a literature review | |
| CN109010811B (en) | Immune preparation of broad-spectrum anti-tumor mouse model by using apoptotic body vaccine | |
| CN116355846A (en) | Method for amplifying activated lymphocytes with stable and controllable quality and application of method in preventing and treating neurologic diseases | |
| TW200404002A (en) | Treatment method achieved by using the lymphocytes derived from HLA matching donor-originating activated lymphocytes, formula having the lymphocytes as a main constituent thereof; method and preparation kit for manufacturing the formula | |
| CN102212505A (en) | Immune killer cell, preparation method thereof, medicinal composition containing immune killer cell and set | |
| CN111184742B (en) | Application of TREM-2+ T cells in preparation of drugs for treating tuberculosis | |
| CN108118030A (en) | A kind of Dendritic Cells culture medium and cultural method | |
| CN109419003A (en) | Breast milk oligosaccharide is preparing the purposes in food or drug | |
| WO2005004789A2 (en) | Method for treating diseases associated with changes of qualitative and/ quantitative composition of blood extracellular dna | |
| CN105616445A (en) | NK cell secreted protein eye drops for treating viral keratitis and preparation method and application thereof | |
| CN104072602A (en) | Preparation method of swine leukocyte interferon | |
| Callera et al. | Evaluation of cytokine profile in the different phases of the autologous hematopoietic stem cell transplantation in patients with multiple myeloma | |
| Hays | Physiology of normal bone marrow |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171226 |